IDYA Stock Forecast & Price Target

IDEAYA Biosciences is viewed favorably because IDE849’s DLL3 program sits in a highly validated, large market with expression in up to 90% of SCLC and 80% of extrapulmonary NECs, while the company’s Phase 1 data showed 73% ORR and 6.7 months median PFS, with only 2% AE discontinuations. The planned Phase 3 study by YE26 and constructive FDA alignment support a credible accelerated-approval path, and the addressable opportunity is substantial, including more than $4.5Bn in hypothetical U.S. TAM and modeled peak U.S. revenue of $690M adjusted or $2.2Bn unadjusted. Its outlook is further strengthened by a pro forma cash balance of about $1.3B after the $345M offering and by additional optionality from darovasertib and the MTAP-del portfolio, which could diversify value beyond DLL3.

IDEAYA Biosciences is exposed to substantial clinical risk because its lead programs, including darovasertib, IDE397, and IDE849, may fail to show sufficient efficacy or safety in ongoing or future trials, which could halt development entirely. The company also faces meaningful regulatory and commercial uncertainty, since approval from the FDA and foreign agencies is required and delays or failures would likely pressure performance, while intense competition from larger biotech and pharmaceutical peers may limit its ability to win market share. Financially, the expectation that it will need additional equity financing to fund development raises dilution risk for existing shareholders, adding to concerns that it may not achieve sales estimates or translate its pipeline into durable value.